MedTrace Logo

To Evaluate the Pharmacokinetics and Safety of AD-208

NCT04214808 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-12-02

No results posted yet for this study

Summary

To evaluate pharmacokinetics and safety of AD-208.

Conditions

Interventions

DRUG

AD-208

Dutasteride 0.2mg

DRUG

Avodart Soft Capsule 0.5mg

Dutasteride 0.5mg

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • Young-Ran Yoon, M.D., Ph.D · Kyungpook National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-03
Primary Completion
2020-02-04
Completion
2020-05-04

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04214808 on ClinicalTrials.gov